GSK3B and non-small cell lung carcinoma: Jing-Qiang Huang et al. suggested that the SRPK1/GSK3β axis promotes gefitinib resistance by activating the Wnt pathway in the form of autophosphorylation and may serve as a potential therapeutic target for overcoming gefitinib resistance in NSCLC [36].